Across TCGA pan-cancer cohorts, ANKRD20A19P Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANKRD20A19P data layer compared with 18 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ANKRD20A19P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANKRD20A19P expression acts as an unfavorable survival marker.

LUSC, CESC, and COAD are the cancer types where ANKRD20A19P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	36	view →
CESC	OS	Median	All	0.206	0.801	<.001	24	view →
COAD	OS	Median	III,IV	0.157	0.791	.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ANKRD20A19P tumor-vs-normal RNA expression · all ANKRD20A19P data types